CPT 81415: Exome Sequence Analysis for Unexplained Disorder
Commercial payers pay $4572 on average nationally for this procedure.
CPT code 81415 describes an exome gene sequence analysis performed by a laboratory analyst to identify genetic variants that may explain an unexplained disorder or syndrome; the service is diagnostic genetic sequencing typically performed in a clinical molecular genetics laboratory and billed for ambulatory outpatient or specialty genetics clinic settings where comprehensive exome sequencing is indicated.
For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.
Customize your policy alerts
Sign up for cpt 81415 policy alerts
Get alerted when payer policies referencing 81415 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 81415 center on BUCA’s mean commercial rate of $4,572.10, which provides a useful midpoint for market comparisons. Blue Cross Blue Shield has the highest dispersion between its 25th and 75th percentiles ($5,427.50 - $3,798.30 = $1,629.20), indicating wider variability in allowed commercial rates, while Aetna’s interquartile spread ($3,824.00 - $1,000.00 = $2,824.00) is even larger, reflecting substantial skew from low-percentile contracts to high outliers.
UnitedHealth Group shows a tighter middle distribution with an IQR of $4,780.00 - $2,007.60 = $2,772.40, and Cigna’s interquartile range is $6,177.50 - $2,444.90 = $3,732.60, the widest of the listed payers. Overall, BUCA’s mean at $4,572.10 sits near the center of commercial market rates, while payer-specific IQRs highlight material differences in how concentrated allowed amounts are across insurers.